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Poliovirus replicons were constructed which contain the internal ribosome entry site (IRES) of encephalomyocarditis virus
(EMCV) substituted for the poliovirus IRES. To monitor gene expression and encapsidation, the gene encoding firefly
luciferase was substituted for the P1 gene. Replicons can be encapsidated following serial passage in the presence of a
recombinant vaccinia virus, VV-P1, which expresses the poliovirus P1 protein following infection. Encapsidation of the
wild-type replicon (PV-Luc) was accomplished at either 33 or 37°C; the lower temperature actually resulted in greater
amounts of encapsidated replicon. In contrast, the replicon with the EMCV IRES element (EMCV-Luc) was not efficiently
encapsidated at 37°C and, following serial passage with VV-P1 at 37°C, was not amplified. EMCV-Luc was efficiently
encapsidated, however, following serial passage with VV-P1 at 33°C. Using the encapsidated EMCV-Luc obtained at 33°C,
we found that cells infected with EMCV-Luc at 33 or 37°C produced similar amounts of luciferase. Encapsidated EMCV-Luc
and PV-Luc had similar thermal stability at 33 and 37°C. A single-round encapsidation analysis revealed that less EMCV-Luc
was encapsidated at 37 than at 33°C; less EMCV-Luc was encapsidated at 33°C compared to PV-Luc at either 37 or 33°C.
The results of our studies suggest that in addition to influencing translation/replication, the IRES region of poliovirus can
function to enhance encapsidation. © 2000 Academic Press
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IINTRODUCTION
The genome of poliovirus is a single-stranded posi-
tive-sense RNA molecule of approximately 7500 nucleo-
tides. The coding region of the poliovirus genome has
been subdivided into three regions, designated P1, P2,
and P3 (Kitamura et al., 1981). The P1 region encodes the
viral capsid proteins, while the P2 and P3 regions en-
code the nonstructural proteins required for poliovirus
replication (Rueckert and Wimmer, 1984; Koch and Koch,
1985). Translation of the viral genome results in a single,
long polyprotein which is subsequently processed by
viral encoded proteases, 2A (Toyoda et al., 1986) and 3C
(Hanecak et al., 1982). The capsid region P1 is pro-
cessed in trans by the viral protease–polymerase fusion
protein 3CD (Jore et al., 1988; Ypma-Wong et al., 1988).
A hallmark of the picornavirus genome is the unusu-
ally long 59 nontranslated region (NTR) (Kitamura et al.,
1981). The 59 NTR of poliovirus is 742 nucleotides in
length and contains at least two elements essential for
the poliovirus life cycle. The first 100 nucleotides of the 59
NTR forms an RNA cloverleaf structure, which has been
shown to be required for replication of the RNA genome
and is important for the regulation of viral protein trans-
lation (Andino et al., 1990, 1993). This RNA cloverleaf
tructure interacts with 3CD and the cellular protein poly
1I
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391rC) binding protein 2 (PCBP2) (Blyn et al., 1996, 1997;
arsley et al., 1997). The differential binding of these two
proteins has been proposed to help facilitate the switch
between RNA replication and translation (Gamarnik and
Andino, 1998).
The majority of the 59 NTR (nucleotides 134–556) is
required for translation initiation of the poliovirus ge-
nome (Nicholson et al., 1991; Iizuka et al., 1995). This
egion, the internal ribosome entry site (IRES), contains
igh RNA secondary structure with several predicted
tem-loops. Translation of the viral genome is initiated in
59 end- and cap-independent manner using the IRES
lement (Pelletier and Sonenberg, 1988). Most members
f the family Picornaviridae have either a type I or a type
I IRES element. Poliovirus, a member of the genus en-
erovirus, and rhinoviruses both contain type I IRES ele-
ents. Aptho- and cardio-viruses, including encephalo-
yocarditis virus (EMCV), have a type II IRES element
Jang et al., 1988, 1990; Duke et al., 1992). Both types of
RES elements perform the same function but with very
ittle sequence or secondary structural homology (Jang et
l., 1990; Sonenberg and Meerovitch, 1990; Hellen and
immer, 1995). Although the IRES elements appear dif-
erent, there is apparently enough similarity in function
uch that the elements can be interchanged and still
esult in an infectious virus (Alexander et al., 1994; Rohll
t al., 1994; Gromeier et al., 1996). For example, the type
I IRES of EMCV can substitute for the poliovirus type I
RES in the context of the poliovirus genome. The result-
0042-6822/00 $35.00
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392 JOHANSEN AND MORROWing virus was stable during viral propagation but dem-
onstrated slower growth and lower virus yield compared
to wild-type poliovirus (Rohll et al., 1994; Gromeier et al.,
1996). Based on the results of these studies, it was
concluded that even though the EMCV IRES is a strong
translational enhancer, there were other features of this
IRES that were not optimized for virus production (Rohll
et al., 1994).
An additional role for the IRES element might be in the
encapsidation of the viral genomic RNA. Early work led
to the proposition that RNA replication and encapsida-
tion were linked such that only recently replicated RNA
molecules could be encapsidated (Baltimore, 1969). Sup-
port for this model was recently obtained from studies by
Nugent et al., who found that only newly synthesized
poliovirus RNAs were packaged in trans by capsids
rovided from a helper virus (Nugent et al., 1999). It was
roposed that a requirement exists for the direct asso-
iation of RNA encapsidation components and the RNA
eplication complex (Nugent et al., 1999). Since newly
eplicated RNA molecules can be either translated or
ncapsidated, early in infection the virus might favor the
ranslation of the viral RNA while at later times encapsi-
ation would predominate. Thus, modification of the
RES within the 59 NTR might influence the balance
etween genomic RNA destined for translation nor en-
apsidation. To further dissect the role of the IRES in
ncapsidation, replicons encoding luciferase were con-
tructed with either the poliovirus IRES (PV-Luc) or the
MCV IRES substituted for the poliovirus IRES (EMCV-
uc). Encapsidation of the replicons was analyzed by
roviding P1 in trans using a recombinant vaccinia virus,
V-P1; serial passage of encapsidated replicons by coin-
ection with VV-P1 allows for the amplification of the
eplicons (Ansardi et al., 1993). We found that, although
he replicon containing the EMCV-IRES element ex-
ressed similar amounts of luciferase to PV-Luc, this
eplicon demonstrated a defect in encapsidation com-
ared to PV-Luc. These results are discussed with re-
pect to a role for the IRES element in the encapsidation
f the poliovirus genome.
RESULTS
omparison of the encapsidation of replicons with
he EMCV-IRES with replicons containing the
oliovirus IRES
Previous studies from this laboratory have described
he construction of poliovirus replicons in which foreign
enes can be substituted for the genes encoding the
apsids (P1) (Choi et al., 1991; Ansardi et al., 1993; Porter
t al., 1995, 1998). Replicons can then be used to study
spects of poliovirus replication, gene expression, and
ncapsidation (Ansardi et al., 1996). To further character-ze the effects of substituting the EMCV IRES for the
oliovirus IRES, we have constructed replicons in which
w
the gene encoding luciferase is substituted for P1 (Fig.
). One replicon, described as EMCV-Luc, encodes the
irst 108 nt of the poliovirus 59 NTR, followed by nt
35–836 of EMCV, and then the luciferase gene in place
f the P1 region. In this construct the luciferase gene is
ollowed by a cleavage site for the 2A protease and the
oliovirus coding sequence for P2 and P3. The final 27
ucleotides of VP1 are present for cleavage of luciferase
n cis from the polyprotein by 2A. To serve as a control,
e constructed a replicon encoding luciferase which
ontains the WT-PV 59 NTR including the PV-IRES ele-
ent (PV-Luc). Note that in contrast to the previously
ublished luciferase replicon (Porter et al., 1998), there
re no poliovirus capsid sequences 59 of the luciferase
oding sequence. We confirmed that transfection of in
itro transcribed RNA for each replicon resulted in rep-
ication and expression of viral proteins. Furthermore, the
evels of luciferase activity correlated with the RNA rep-
ication and expression of poliovirus proteins (e.g., 3CD)
rom the replicon, a result which is consistent with our
revious studies (Porter et al., 1998).
Replicons can be encapsidated into virions by provid-
ng P1 in trans from a recombinant vaccinia virus, VV-P1,
hich encodes the P1 capsid precursor protein (Ansardi
t al., 1993). To encapsidate replicons, the in vitro tran-
cribed RNA was transfected into HeLa H1 cells, previ-
usly infected with VV-P1; serial passage of the replicons
as performed in VV-P1-infected cells to generate stocks
f the encapsidated replicons. Encapsidation was deter-
ined by infecting cells with lysates from various pas-
ages and measuring luciferase activity. Analysis of the
uciferase activity following infection of cells with PV-Luc
evealed a continued increase at sequential passages
Fig. 2A). Visual inspection of the cultures revealed a
lear poliovirus-like cytopathic effect (CPE), consistent
FIG. 1. Construction of luciferase containing replicons. The WT-PV
cDNA was engineered to create PV-Luc (A) or EMCV-Luc (B). Both
replicons contain an identical sequence 39 of the luciferase gene
including the 2A cis cleavage site. PV-Luc encodes the entire 59 NTR of
oliovirus, from nt 1 to the AUG start codon at nt 743. EMCV-Luc
ncodes the first 108 nt of poliovirus followed by the EMCV-IRES and
tart codon for translation initiation (nts 335–856 of EMVC).ith the presence of encapsidation of replicons. In con-
rast, we did not see an increase in the amount of
A
a
i
B
s
p
f
a
n B and
39359 NTR INVOLVEMENT IN POLIOVIRUS ENCAPSIDATIONEMCV-Luc, as measured by luciferase activity during
serial passage with VV-P1 at 37°C; furthermore poliovi-
rus-like CPE was not evident. In fact, at later passes
(greater than pass 8), only background levels of lucif-
erase activity were detected from cells infected with
EMCV-Luc lysates (Fig. 2B). To determine whether the
replicon was lost from the passages, we used immuno-
precipitation with antibodies to 3DPol. No 3DPol-containing
proteins were immunoprecipitated from the metaboli-
cally labeled cells infected with passage 8 material.
Finally, we confirmed the lack of the replicons by RT-PCR
using primers specific for the replicons (data not shown).
Taken together, the results of these studies show that
although EMCV-Luc was encapsidated at 37°C, serial
passage at this temperature did not result in the estab-
lishment of a replicon stock as was the case for PV-Luc
(Figs. 2A and 2B).
To further explore the nature of the differences be-
tween PV-Luc and EMCV-Luc, we analyzed a variety of
different conditions for trans encapsidation. Modification
of the transfection protocol resulted in an increase in the
FIG. 2. Analysis of the encapsidation of PV-Luc and EMCV-Luc from t
under Materials and Methods. The level of luciferase activity from the
amounts. Serial passage of the two luciferase replicons was carried out
aliquots from specific passages were used to infect cells followed by
shown in A and C while the analysis of EMCV-Luc passages is shown i
of replicon stock.number of cells transfected but not the amplification of
the EMCV-Luc replicon following serial passage with
t
MVV-P1 at 37°C. The encapsidation protocol was also
modified so that replicon RNA was first introduced to the
cell and, 8 h later, VV-P1 was used to infect the cells.
Although altering the timing of the VV-P1 infection did
slightly increase the levels of encapsidated replicon, the
EMCV-Luc replicon still did not amplify following serial
passage. Again, metabolic labeling of supernatants from
later passages of EMCV-Luc at 37°C revealed no polio-
virus proteins, confirming the loss of the replicon (data
not shown).
Previous studies have indicated that encapsidation
and/or particle formation can occur at temperatures
lower than 37°C (Brautigam et al., 1993; Gamarnik and
ndino, 1996). Lower incubation temperatures (33–35°C)
re many times more favorable for the production of virus
n vitro (Molla et al., 1991; Barton and Flanegan, 1993;
arton et al., 1995). In an attempt to find conditions
uitable for propagation of EMCV-Luc then, we first com-
ared the encapsidation of PV-Luc at 37 and 33°C. We
ound that PV-Luc was also readily encapsidated at 33°C
nd, in fact, grew to higher titers than matched prepara-
tion. Transfection of PV-Luc or EMCV-Luc was performed as described
ted samples was determined and used to start passage 1 with equal
(A and B) or 33°C (C and D). As a measure of encapsidation, matched
s for luciferase activity. The analysis from serial passage of PV-Luc is
D. The data are presented as relative light units per milliliter (RLU/ml)ransfec
transfec
at 37°C
analysiions serially passaged with VV-P1 at 37°C (Fig. 2C).
ost surprisingly, EMCV-Luc was also encapsidated and
394 JOHANSEN AND MORROWamplified after serial passage at 33°C (Fig. 2D). Using
these new conditions, we were able to obtain stocks of
the encapsidated EMCV-Luc that could be used to
investigate the nature of the defect in amplification
at 37°C.
One possibility for the inability to amplify the replicon
FIG. 3. Analysis of the amplification of EMCV-Luc (A) and PV-Luc (B)
using encapsidated replicons. Equivalent amounts of encapsidated
replicons (designated S for starting amount) were used to initiate a
six-passage serial encapsidation experiment comparing propagation
at the two temperatures, 33 or 37°C. Luciferase activity was deter-
mined after passage 3 and passage 6. The data are represented as
total RLV for the entire passage sample.
FIG. 4. Luciferase expression following infection with encapsidated re
at 37°C (A) or 33°C (B). At various times postinfection, cell lysates we
representative of several independent experiments. C and D. Replicon
at 30, 33, or 37°C. After 2, 4, 6, and 12 h of incubation, an aliquot was harveste
activity (RLU). C: PV-Luc. D: EMCV-Luc. Incubation temperatures are as notedat 37°C was that a low number of cells transfected, when
coupled with a lower efficiency of encapsidation, might
result in the inability to propagate EMCV-Luc at 37°C. To
address this possibility, comparable amounts of encap-
sidated EMCV-Luc (prepared at 33°C), sufficient to infect
all of the cells in the culture, were passaged with VV-P1
at 33 or 37°C (Fig. 3A). EMCV-Luc passaged with VV-P1
at 37°C again failed to amplify following serial passage,
while the titer of EMCV-Luc in the presence of VV-P1 at
33°C increased following six serial passages. The rela-
tive increase for EMCV-Luc passaged at 33°C was com-
parable to those of PV-Luc at passages at 37°C (Fig. 3B),
but not as substantial as amplification of PV-Luc follow-
ing serial passage at 33°C (Fig. 3B).
Further characterization of EMCV-Luc encapsidation
The inability to propagate the EMCV-Luc replicon at
37°C might be due to a temperature-sensitive defect in
translation/replication or virion stability. To address
these two possibilities, luciferase expression was com-
pared for both EMCV-Luc and PV-Luc at 33 or 37°C (Figs.
4A and 4B). Both replicons expressed slightly greater
levels of luciferase at 37°C compared with 33°C, which
is in contrast with greater amplification of the replicon
. Equal multiplicity of infection of each replicon was used to infect cells
ested and luciferase activity was determined. The data presented are
y at different temperatures. Equal amounts of replicon were incubatedplicons
re harv
stabilitd and used to infect cells, followed by determination of total luciferase
.
f cells
E were
39559 NTR INVOLVEMENT IN POLIOVIRUS ENCAPSIDATIONstock at 33 than 37°C. Most importantly, no drastic tem-
perature sensitivity was seen for luciferase expression
from EMCV-Luc at 37°C compared to expression from
PV-Luc (Fig. 4A).
Another possibility for the inability to amplify EMCV-
Luc at 37°C might be thermal instability of the virions. To
address this possibility, we compared the infectivity of
EMCV-Luc and PV-Luc after incubation at 30, 33, and
37°C. After 2, 4, 6, and 12 h a sample was removed from
each temperature and used to infect cells and analyze
luciferase activity. All infections were done at 37°C since
the expression of luciferase from EMCV-Luc or PV-Luc
was similar at this temperature. Similar amounts of lu-
ciferase expression were detected from cells infected
with EMCV-Luc or PV-Luc incubated at 30, 33, or 37°C for
the indicated times (Figs. 4C and 4D). Thus, there was no
indication that the encapsidated EMCV-Luc replicons
were thermally unstable following prolonged incubation
FIG. 5. Single-round encapsidation analysis of PV-Luc and EMCV-Lu
infection of cells in the presence of VV-P1 or wild-type vaccinia virus (VV
of PV-Luc (A and B) or EMCV-Luc (D and E); parallel infections were set u
luciferase expression was determined at the designated time points po
analyzed at the designated time points for encapsidation by reinfection o
assay (closed circles). A, C, D, and F were incubated at 37°C; B andat 37°C.
The defect observed in the propagation of EMCV-Lucat 37°C is manifested over serial passage with VV-P1 at
this temperature. To further explore the role that a defect
in encapsidation might influence the inability to propa-
gate EMCV-Luc at 37°C, we analyzed the encapsidation
during a single-round infection cycle at 37 and 33°C (Fig.
5). For these studies, infections were initiated with either
PV-Luc or EMCV-Luc at 37 or 33°C in the presence of
VV-P1 or wild-type vaccinia virus (VV-WR). At the desig-
nated time points, the amounts of luciferase activity in
the infected cells were determined and the cells and
supernatant were processed and used to determine lev-
els of encapsidated replicons. A comparison of the
amounts of encapsidated replicons recovered from a
single round of infection at 37°C for PV-Luc and EMCV-
Luc revealed lower levels of encapsidated replicons con-
taining the EMCV-IRES element compared with the rep-
licon with the PV-IRES. Although luciferase levels are
similar for the two replicons at 37°C, about 10-fold less
single-round encapsidation of PV-Luc or EMCV-Luc was analyzed by
ells were infected with VV-P1 followed by infection with equal amounts
ting cells with VV-WR and PV-Luc (C) or EMCV Luc (F). The intracellular
tion (open diamonds). A parallel infection (cells and supernatants) was
followed by determination of the levels of luciferase using the standard
incubated at 33°C.c. The
-WR). C
p infec
stinfecencapsidated EMCV-Luc was recovered from a single-
round encapsidation compared with PV-Luc (Figs. 5A
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396 JOHANSEN AND MORROWand 5D). At 33°C, about 5-fold less encapsidated EMCV-
Luc was recovered compared with PV-Luc (Figs. 5B and
5E). This difference was due to the amount of encapsi-
dated replicons because no luciferase activity was de-
tected if the VV-P1 was substituted with wild-type vac-
cinia virus, which does not provide the capsid in trans
(Figs. 5C and 5F). The results of our single-round infec-
tion assays then support our previous results comparing
the propagation of PV-Luc and EMCV-Luc at 37 and 33°C
and point to an alteration in the efficiency of encapsida-
tion of EMCV-Luc compared to PV-Luc.
DISCUSSION
Previous studies have described chimeric polioviruses
in which the IRES from coxsackievirus B3 (CVB3) (Semler
et al., 1986), EMCV (Rohll et al., 1994; Gromeier et al.,
996), human poliovirus 14 (HRV14) (Gromeier et al.,
996), or hepatitis C virus (Lu and Wimmer, 1996) have
een substituted for the poliovirus IRES. All of the recom-
inant viruses exhibited a small plaque phenotype and
elayed virus production compared to the wild-type vi-
us. One aspect of the viral replication cycle that was
ifficult to study was the effect that the IRES element had
n encapsidation. Some of this is due to the fact that
any elements of the encapsidation process for poliovi-
us still remain unknown. Recent studies have suggested
link between genome and encapsidation; only those
enomes which have been recently synthesized (repli-
ated) are encapsidated (Nugent et al., 1999). The plus
trand viral genome of poliovirus then would have three
ossible fates in the cell; one would be to serve as a
emplate for synthesis of minus strands, a second would
e for translation of new viral proteins, and the third
ould be to undergo encapsidation required for subse-
uent virus propagation. While these fates are not mu-
ually exclusive, the virus most probably has evolved a
echanism to prevent translation of genome RNAs des-
ined to be encapsidated. To further explore the role the
RES has on encapsidation, we utilized a system in
hich replication/translation can be disengaged from
ncapsidation. These studies relied on the use of RNA
enomes (replicons) in which the P1 gene has be sub-
tituted with the gene encoding luciferase. Although PV-
uc and EMCV-Luc both replicated and expressed lucif-
rase upon transfection, only propagation of the replicon
ncoding luciferase with the wild-type IRES (PV-Luc) was
eadily accomplished at 37°C and 33°C. Amplification of
V-Luc was evident upon serial passage in the presence
f VV-P1. The effect of the IRES element on encapsidation
as manifested upon examination of the amplification of
MCV-Luc. We were unable to amplify the EMCV-Luc
eplicon at 37°C; only after serial passage at 33°C were
e able to amplify the encapsidated replicon sufficientlyo obtain stocks of this replicon. Characterization of
MCV-Luc obtained from passage at 33°C revealed that
c
whe replicon still was infection competent and could
eplicate at 37°C. In fact, infection of cells at 37°C with
ncapsidated EMCV-Luc, grown at 33°C, resulted in sim-
lar levels of protein expression and RNA replication
ompared to PV-Luc. Thus, from our analysis, we con-
lude that there was no inherent temperature-sensitive
efect in the translation/replication of EMCV-Luc that
ould completely account for the inability to amplify
pon passage with VV-P1 at 37°C. The encapsidated
MCV-Luc also did not show major differences in virion
tability at 37°C compared to PV-Luc, establishing that
he encapsidated EMCV-Luc was not inactivated during
he serial passages at 37°C.
The results from our study support the idea that the
RES element plays a role in encapsidation, although it is
mportant to note that we do not believe that the IRES
lement is an encapsidation signal. The specificity of
oliovirus RNA genome encapsidation is most probably
ependent upon several factors, including covalently
inked VPg and positive-strand polarity. The IRES alone
annot be the only encapsidation signal, as substitution
f the PV IRES with that of EMCV or other picornaviral
RES elements still allowed for encapsidation by poliovi-
us capsids. Also, the EMCV-IRES replicon could not be
ncapsidated by EMCV capsids indicating that the spec-
ficity for encapsidation is more complex than just the
RES element (Johansen and Morrow, unpublished ob-
ervations).
Our results are consistent with the concept that the
RES plays a role in encapsidation, possibly acting to
nhance the efficiency. The single-round encapsidation
nalysis highlights the subtle, but clear, differences be-
ween the encapsidation of PV-Luc and EMCV-Luc at
7°C which, when amplified over several serial pas-
ages, could account for the inability to obtain stocks of
MCV-Luc. Further support for EMCV-Luc having a de-
ect in encapsidation comes from a comparison with
V-Luc at 33°C, where we found similar levels of lucif-
rase activity for both replicons, but PV-Luc was encap-
idated more efficiently following a single cycle than
MCV-Luc. What might account for the differences seen
n the encapsidation between PV-Luc and EMCV-Luc?
ne possibility is that interaction of P1, or subviral (14S)
articles, with the IRES might be necessary for efficient
ncapsidation. Previous studies have shown that 14S
entamers interact with replication complexes (Nugent
t al., 1999). It is possible the interaction of 14S penta-
ers with the IRES prevents, or retards, the translation of
he replicon genome, which might then be a better sub-
trate for encapsidation. Although there exists enough
imilarity with the EMCV-IRES to substitute for the polio-
irus IRES, subtle differences in RNA sequence or struc-
ure might influence interaction with P1 or 14S penta-
ers that would effect encapsidation. Alternatively, it
ould be that P1 or 14S pentamers displace or compete
ith cellular factors which bind to the IRES and promote
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39759 NTR INVOLVEMENT IN POLIOVIRUS ENCAPSIDATIONtranslation. Differences with respect to the cellular fac-
tors which bind the poliovirus and EMCV-IRES might
result in an inability of the EMCV-Luc to clear the ge-
nome necessary to promote encapsidation. Lowering the
incubation temperature to 33°C might shift the balance
between P1 (or 14S pentamers) interacting with the IRES
compared to the cellular factors such that encapsidation
can reach a threshold to allow enough EMCV-Luc for
efficient propagation. Further experiments using the rep-
licon system to control the levels and timing of P1 ex-
pression will be required to address these issues of
poliovirus encapsidation.
MATERIALS AND METHODS
Construction of replicons encoding luciferase
The plasmid, pT7-IC-CEAsig- (Ansardi et al., 1994),
was used for replicon constructs and encodes an engi-
neered XhoI cloning site following the AUG of the polio-
virus 59 NTR. pT7-IC-CEAsig- was digested with XhoI and
SnaBI to remove the foreign gene (CEA) and the lucif-
erase gene was cloned from the plasmid pGEM-Luc
(Promega) using the following primers (59-CTCGAGGAA-
GACGCCAAAAACATAAAG-39) and (59-GTTAACCAATTT-
GGACTTTCCGCC-39), which created an XhoI site at the
59 end of the luciferase gene and a HpaI site at the 39
end. The modified luciferase gene fragment was sub-
cloned into the XhoI–SnaBI digested pT7-IC-CEAsig-re-
placing the foreign gene sequence with luciferase; the
resulting plasmid was designated pPV-Luc to distinguish
this construct from our previous replicon which con-
tained the VP4 gene of poliovirus positioned before the
luciferase gene (Porter et al., 1998). The replicon in which
the EMCV IRES was substituted for the polio IRES,
EMCV-Luc, was created as follows. Two DNA primers RI
(59-CCAGTGAATTCCTAATACGACTCACTATAGGTTAAAA-
CAG-39) and 108-PV (59-GCAATATGGTGGAAAATAAC-
CTAAGTTACGGGA AGG-39) were used to PCR the first
108 nucleotides (nt) of PV from the infectious cDNA
pT7-IC; included in the 59 primer sequence is the DNA
corresponding to the promoter for the T7 DNA-depen-
dent RNA polymerase. The inclusion of the T7 promoter
allows for in vitro transcription with the corresponding
transcript containing two additional G nucleotides at the
59 end (Choi et al., 1991). Primer 108-PV created a 39
overhang which was complementary to the 59 end of the
EMCV-IRES. This PCR product was used as a mega-
primer along with primer CITE-VP4-2 (59-CCACTTTCTGT-
GATGAAACCTGAGCACCCATATTATCATCGTGTTTTTC-39)
to PCR the EMCV-IRES from the vector pCITE-4a (Nova-
gen). The resulting PCR product was then used as tem-
plate DNA, along with primer SalI39 (59-GGTCGACCCA-
CCATACGCTCTATTTGAGTTTCATGTGCGCCCACTTTCT-
GTGAG-39) which created a SalI restriction site at the 39
end of the 108-EMCV-IRES fragment. Two silent muta-
tions at nts 808 (T3 G) and 811 (T3 G) in the poliovirus
r
pcoding sequence were created by PCR mutagenesis to
create a SalI cloning site. Primer Sal59 (59-GTGGGTC-
GACCATTAATTACACCACC-39) and primer SnaB2956 (59-
CCGGGCTGGAGCTGTTCC-39) were used to amplify nts
904 to 3058 of WT-PV cDNA, creating a SalI site at the 59
end of the PCR product. The 108-EMC-AUG-SalI and the
SalI to 3058 fragment were subcloned into the PV cDNA
plasmid, pT7-IC. The newly synthesized region was con-
firmed by DNA sequencing and the resultant cDNA des-
ignated EMCV-IRES-PV. Note that the nucleotides altered
to create the SalI restriction site used in cloning do not
alter the amino acids encoded in P1 from the wild-type
genome. Using primers RI and CITE-4-Xho (59-CTCG-
AG ATGGGTGGTGGCCATATTATC-39) with the EMCV-
IRES-PV as the template DNA, the PCR reaction created
a XhoI site at the 39 end of the EMCV-IRES. The EcoRI–
XhoI fragment was cloned in place of the EcoRI–XhoI
partial digest from pPV-Luc; the resultant plasmid was
named pEMCV-Luc. DNA sequencing of the 59 NTR of all
of the resultant plasmids confirmed the presence of the
desired changes.
Encapsidation of replicons
The encapsidation and serial passage of poliovirus
replicons using VV-P1 have been described previously
(Porter et al., 1993; Ansardi et al., 1993). Briefly, HeLa H1
ells were infected with 10 pfu of VV-P1 per cell. At 3 h
ostinfection, the cells were transfected by the DEAE–
extran method (Choi et al., 1991) with in vitro tran-
scribed RNA from linearized plasmids pPV-Luc and
pEMCV-Luc. The cultures were harvested 24 or 48 h after
transfection by three freeze–thaw cycles, overlaid on a
30% sucrose cushion (30% sucrose, 30 mM Tris, pH 8.0,
and 0.1 mM NaCl), and subjected to centrifugation in an
SW41 rotor (Beckman) at 40,000 rpm overnight. Superna-
tants were discarded and the pellets were resuspended
in serum-free DMEM and used for serial passage.
For serial passage of the encapsidated replicons,
HeLa H1 cells were infected with 10 pfu of VV-P1 per cell.
After 3 h, the cells were infected with the encapsidated
replicon supernatant. Cultures were harvested 24 or 48 h
postinfection by three successive freeze–thaw cycles
and were clarified by centrifugation at 14,000g for 20
in. These supernatants were stored at 270°C or used
or additional passages by the same procedure. When
he encapsidation procedure was performed at 37°C,
4-h infections were used. At 33°C, the encapsidation
as allowed to proceed for 48 h.
uciferase assay
For analysis of luciferase protein expression from rep-
icons, HeLa H1 cells were infected and harvested at the
esignated times by washing once with PBS and thenesuspending the cells in 1 ml PBS. The cells were
elleted for 6 min at 14,000g and the PBS was removed;
398 JOHANSEN AND MORROW100 ml of 13 lysis buffer (Promega, Madison, WI) was
used to resuspend the cell pellet. The samples were
assayed for light detection using a luminometer (Moon-
light 2010, Analytical Luminescence Laboratories) (Porter
et al., 1998). The raw relative light unit (RLU) data were
used to calculate the total RLU in a sample or the RLU
per milliliter. All infections for the determination of lucif-
erase activity went overnight (15 h) at 37°C unless oth-
erwise specified.
Single-cycle encapsidation assay
Similar amounts of replicons PV-Luc and EMCV-Luc
were coinfected with VV-P1 or VV-WR (wild-type vaccinia
virus)). VVP1 (to provide P1 for encapsidation) or VV-WR
was used at an m.o.i. of 10 to infect HeLa HI cells 3 h
prior to replicon infection. Encapsidated replicons were
used to infect two wells per time point at 37 or 33°C. At
4, 10, 24, and 48 h post-replicon-infection samples were
harvested to measure luciferase protein expression and
levels of encapsidated replicon. One well was washed
once with PBS and cells were harvested to measure
luciferase expression from the initial replicon infection.
Both supernatant and cells were harvested from the
second well; the samples were freeze–thawed three
times and used to reinfect cells. Luciferase activity was
determined at 15 h postreinfection. All luciferase assays
were measured on the same day.
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